logo-loader

Scancell Holdings gets green light for South African COVID-19 trial

Published: 07:36 29 Jul 2021 BST

Scancell Holdings PLC -

Scancell Holdings PLC (LSE:SCLP, FRA:SCP) (LON:SCLP) said its phase I clinical trial of a potential next-generation Coronavirus (COVID-19) vaccine has been given the green light by South African regulators.

The two-part study, which is set to get underway sometime in the second half, will look at both safety and immunogenicity – the ability to provoke an immune response.

The COVIDITY programme is a collaboration between Scancell, scientists in the newly established Centre for Research on Global Virus Infections and the Biodiscovery Institute at the University of Nottingham, and Nottingham Trent University.

The plan is to test the potential of Scanell’s SCOV1 and SCOV2, which were developed using the company’s ImmunoBody platform, to tackle both the original SARS-CoV-2 virus and its variants.

Following sign-off by the South African Health Products Regulatory Authority (SAHPRA), the project, which has funding from Innovate UK, will begin at the University of Cape Town Lung Institute and will involve unvaccinated, healthy adult volunteers.

Part two will take place in South Africa and Britain. After a demonstration of safety, the company will seek approval from the Medicines & Healthcare Products Regulatory Agency to begin an extension of the study in which SCOV2 will be given to healthy volunteers who have already received two doses of an approved vaccine.

Scancell chief executive, professor Lindy Durrant, said: “We are very pleased that this clinical trial application was approved so rapidly, reflecting the importance of the study in South Africa, and it is a testament to the dedication and professionalism of the Scancell team and our colleagues in Cape Town.”

Scancell CEO hails "exciting" high response rate to melanoma treatment

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) chief executive Professor Lindy Durrant speaks to Thomas Warner from Proactive to provide an update on the initial phase of the clinical stage biopharmaceutical company's Phase 2 SCOPE trial in advanced melanoma. Professor Durrant gives an overview...

on 19/9/23